» Articles » PMID: 23964037

Acute Respiratory Failure Secondary to Mesalamine-induced Interstitial Pneumonitis

Overview
Journal BMJ Case Rep
Specialty General Medicine
Date 2013 Aug 22
PMID 23964037
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Interstitial pneumonitis as an adverse effect of mesalamine therapy is a rare but potentially serious complication. Patients typically have a mild disease course with no documented cases of respiratory failure in published literature. Given its variable latent period and non-specific signs and symptoms, it may be difficult to diagnose. We present the case of a 65-year-old man who presented with symptoms of fever, shortness of breath and a non-productive cough, 2 weeks after initiation of therapy with mesalamine. His hospital course was complicated by acute respiratory failure requiring intubation and mechanical ventilation. Radiographic studies revealed bilateral lower lobe infiltrates and bronchosopy with bronchoalveolar lavage and transbronchial biopsy were consistent with a diagnosis of drug-induced interstitial pneumonitis. The aim of this paper is to highlight the importance of considering a diagnosis of mesalamine-induced lung injury in patients presenting with respiratory symptoms while on mesalamine therapy and to review relevant literature.

Citing Articles

Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections.

Cavalli C, Gabbiadini R, Dal Buono A, Quadarella A, De Marco A, Repici A J Clin Med. 2023; 12(19).

PMID: 37835065 PMC: 10573999. DOI: 10.3390/jcm12196419.


Nonasthmatic eosinophilic bronchitis in an ulcerative colitis patient - a putative adverse reaction to mesalazine: A case report and review of literature.

Cernomaz A, Bordeianu G, Terinte C, Gavrilescu C World J Clin Cases. 2020; 8(18):4162-4168.

PMID: 33024774 PMC: 7520771. DOI: 10.12998/wjcc.v8.i18.4162.


Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation.

Oi H, Suzuki A, Yamano Y, Yokoyama T, Matsuda T, Kataoka K Respir Med Case Rep. 2020; 31:101157.

PMID: 32953447 PMC: 7486608. DOI: 10.1016/j.rmcr.2020.101157.


Organizing pneumonia: a rare pulmonary manifestation of well-controlled ulcerative colitis.

Zhou X, Chen Y, Zhao L J Thorac Dis. 2018; 10(8):E634-E638.

PMID: 30233901 PMC: 6129940. DOI: 10.21037/jtd.2018.07.102.


Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.

Ferrusquia J, Perez-Martinez I, Gomez de la Torre R, Fernandez-Almira M, de Francisco R, Rodrigo L World J Gastroenterol. 2015; 21(13):4069-77.

PMID: 25852295 PMC: 4385557. DOI: 10.3748/wjg.v21.i13.4069.


References
1.
Matsuno O . Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012; 13:39. PMC: 3426467. DOI: 10.1186/1465-9921-13-39. View

2.
Moss A, Peppercorn M . The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf. 2007; 6(2):99-107. DOI: 10.1517/14740338.6.2.99. View

3.
Loftus Jr E . Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126(6):1504-17. DOI: 10.1053/j.gastro.2004.01.063. View

4.
Meier J, Sturm A . Current treatment of ulcerative colitis. World J Gastroenterol. 2011; 17(27):3204-12. PMC: 3158396. DOI: 10.3748/wjg.v17.i27.3204. View

5.
Cilloniz R, Chesrown S, Gonzalez-Peralta R . Asymptomatic presentation of mesalamine-induced lung injury in an adolescent with Crohn disease. BMJ Case Rep. 2011; 2009. PMC: 3027507. DOI: 10.1136/bcr.09.2008.0908. View